Burkitt Lymphoma - Pipeline Review, H2 2011

Global Markets Direct, August 2011, Pages: 88

Burkitt Lymphoma - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Burkitt Lymphoma - Pipeline Review, H2 2011', provides an overview of the Burkitt Lymphoma therapeutic pipeline. This report provides information on the therapeutic development for Burkitt Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Burkitt Lymphoma. 'Burkitt Lymphoma - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Burkitt Lymphoma.
- A review of the Burkitt Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Burkitt Lymphoma pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Burkitt Lymphoma.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Burkitt Lymphoma pipeline depth and focus of Burkitt Lymphoma therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Burkitt Lymphoma Overview
Therapeutics Development
An Overview of Pipeline Products for Burkitt Lymphoma
Burkitt Lymphoma Therapeutics under Investigation by Universities/Institutes
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Burkitt Lymphoma Therapeutics - Products under Investigation by Universities/Institutes
Burkitt Lymphoma - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
LBH589 + RAD001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rapamycin + Etoposide + Cytarabine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
doxorubicin + vincristine + cyclophosphamide + prednisone + rituximab + yttrium Y 90 ibritumomab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Filgrastim + Rituximab + Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin hydrochloride + Etoposide + Ifosfamide + Leucovorin calcium + Methotrexate + Prednisone + Vincristine sulfate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rituximab + Methotrexate + Cytarabine + G-CSF + Radiation therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
R-CODOX-M + Leucovorin + Filgrastim + Cytarabine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
R-CODOX-M + Leucovorin + Filgrastim + IVAC - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cyclophosphamide + Vincristine sulfate + Prednisone + Rituximab + Methotrexate + Leucovorin calcium + Cytarabine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cyclophosphamide + Vincristine + Prednisone + Doxorubicin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cyclophosphamide + Vincristine + Prednisone + Methotrexate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cyclophosphamide + Vincristine + Prednisone + Cytarabine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RITUXIMAB - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rituximab + Hyper-CVAD - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Treanda + Carboplatin + Rituximab + Etoposide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Treg Cells + CD3-Teff Cells + Fludarabine + Cyclophosphamide + Radiation Therapy + Umbilical Cord Blood Transplantation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Filgrastim + Cyclophosphamide + Cytarabine + Doxorubicin hydrochloride + Etoposide + Ifosfamide + Leucovorin calcium + Methotrexate + Vincristine sulfate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Filgrastim + Cyclophosphamide + Cytarabine + Doxorubicin hydrochloride + Etoposide + Ifosfamide + Leucovorin calcium + Methotrexate + Vincristine sulfate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Filgrastim + Pegfilgrastim + Rituximab + Cyclophosphamide + Cytarabine + Doxorubicin Hydrochloride + Etoposide + Ifosfamide + Leucovorin Calcium + Liposomal Cytarabine + Methotrexate + Therapeutic Hydrocortisone + Vincristine Sulfate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rituximab + Cyclophosphamide + Doxorubicin + Vincristine + Methotrexate + Leucovorin + Cytarabine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rituximab + Cyclophosphamide + Doxorubicin + Vincristine + Methotrexate + Leucovorin + Ifosfamide + Etoposide + Cytarabine + Mesna - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Prednisone + Vincristine + Cytarabine + Methotrexate + Etoposide + Cyclophosphamide + Doxorubicin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Busulfan + Cyclophosphamide + Anti-Thymocyte Globulin + Methylprednisolone + Cyclosporine + Mycophenolate Mofetil + Allogeneic Hematopoietic Stem Cell Transplantation + Umbilical Cord Blood Transplantation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Filgrastim + Pegfilgrastim + Rituximab + Cyclophosphamide + Cytarabine + Leucovorin calcium + Methotrexate + Prednisone + Therapeutic hydrocortisone + Vincristine sulfate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RAD001 + Lenalidomide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rituximab + Lenalidomide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Amplimexon - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rituximab + Cyclophosphamide + Prednisone + Dexamethasone + Vincristine + Methotrexate + Ifosphamide + Teniposide + Etoposide + Cytarabine + Adriamycin + Vindesine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LBH589 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Burkitt Lymphoma Therapeutics - Discontinued Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Burkitt Lymphoma, H2 2011
Products under Development for Burkitt Lymphoma – Comparative Analysis, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Comparative Analysis by Mid Clinical Stage Development, H2 2011
Comparative Analysis by Early Clinical Stage Development, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Discontinued Products

List of Figures
Number of Products under Development for Burkitt Lymphoma, H2 2011
Products under Development for Burkitt Lymphoma – Comparative Analysis, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Mid Clinical Stage Products, H2 2011
Early Clinical Stage Products, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products, H2 2011
Assessment by Route of Administration, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Assessment by Stage and Molecule Type, H2 2011

Customers who bought this item also bought

• Lymphoma - Pipeline Review, H2 2012
• Non-Hodgkin Lymphoma - Pipeline Review, H2 2012
• Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy - Pipeline Review, H2 2012
• Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H2 2012
• Primitive Neuroectodermal Tumor (PNET) - Pipeline Review, H2 2012
• Brain Cancer - Pipeline Review, H2 2012
• Chronic Lymphoblastic Lymphoma - Pipeline Review, H2 2012
• Other Hematological Disorders - Pipeline Review, H2 2012
• Non-Hodgkin Lymphoma - Pipeline Review, Q4 2010
• Myeloproliferative Disorders - Pipeline Review, H2 2012